Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 3
1983 1
1990 1
1992 1
1993 1
1996 2
1998 2
1999 4
2000 4
2001 4
2002 3
2003 5
2004 11
2005 10
2006 12
2007 15
2008 16
2009 8
2010 16
2011 13
2012 11
2013 12
2014 4
2015 5
2016 2
2017 4
2019 2
2020 4
2021 6
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Results by year

Filters applied: . Clear all
Page 1
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
miRNA Stability in Frozen Plasma Samples.
Balzano F, Deiana M, Dei Giudici S, Oggiano A, Baralla A, Pasella S, Mannu A, Pescatori M, Porcu B, Fanciulli G, Zinellu A, Carru C, Deiana L. Balzano F, et al. Among authors: deiana l. Molecules. 2015 Oct 20;20(10):19030-40. doi: 10.3390/molecules201019030. Molecules. 2015. PMID: 26492230 Free PMC article.
Plasma L-ergothioneine measurement by high-performance liquid chromatography and capillary electrophoresis after a pre-column derivatization with 5-iodoacetamidofluorescein (5-IAF) and fluorescence detection.
Sotgia S, Pisanu E, Pintus G, Erre GL, Pinna GA, Deiana L, Carru C, Zinellu A. Sotgia S, et al. Among authors: deiana l. PLoS One. 2013 Jul 29;8(7):e70374. doi: 10.1371/journal.pone.0070374. Print 2013. PLoS One. 2013. PMID: 23922985 Free PMC article.
Genetics of healthy aging in Europe: the EU-integrated project GEHA (GEnetics of Healthy Aging).
Franceschi C, Bezrukov V, Blanché H, Bolund L, Christensen K, de Benedictis G, Deiana L, Gonos E, Hervonen A, Yang H, Jeune B, Kirkwood TB, Kristensen P, Leon A, Pelicci PG, Peltonen L, Poulain M, Rea IM, Remacle J, Robine JM, Schreiber S, Sikora E, Slagboom PE, Spazzafumo L, Stazi MA, Toussaint O, Vaupel JW. Franceschi C, et al. Among authors: deiana l. Ann N Y Acad Sci. 2007 Apr;1100:21-45. doi: 10.1196/annals.1395.003. Ann N Y Acad Sci. 2007. PMID: 17460163 Review.
172 results